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Abstract
Background: Isoniazid preventive therapy (IPT) is a recommended strategy for prevention of tuberculosis (TB) in
persons with Human Immunodeficiency Virus (HIV) although the benefits have not been unequivocally
demonstrated in routine clinical practice with widespread ART adoption. Therefore, we assessed the effectiveness of
IPT in prevention of TB or death in patients treated with antiretroviral therapy (ART) in a chronic care setting.
Methods: Retrospective cohort study of HIV patients enrolled in chronic care from 2007 to 2013. Eligible
participants were HIV infected subjects (age > 15 years) with no (history of) TB. The combined effect of IPT and ART
on the composite outcome (TB or death) was estimated using time-dependent Cox regression with adjustment for
baseline covariates.
Results: 1,922 patients were included, 374 (19.4 %) received IPT and 258 (13.4 %) developed TB or deceased. The
median follow-up duration of the cohort was 839 days, with a total of 5491 person years. In unadjusted analysis,
the combination of IPT and ART lowered the hazard of TB or death by 65 % [HR = 0.35; 95 % CI (0.16, 0.77)]
compared to ART alone. Even after adjustment for confounders, the combined effect of ART and IPT resulted in a
60 % hazard reduction of TB or death in comparison to participants who received ART without IPT [HR = 0.40; 95 %
CI (0.18, 0.87)]. The IPT-specific benefit in patients not receiving ART could not be reliably estimated due to high
rates of ART adoption.
Conclusion: The combined effect of IPT and ART to prevent TB or death in HIV patients in a non-experimental
setting in comparison to ART alone was estimated to be 60 %.
Background
The World Health Organization (WHO) has estimated
that in 2013 nine million people developed tuberculosis
(TB) with 1.5 million associated deaths, including 360.000
among persons with Human Immunodeficiency Virus [1].
Although the introduction of anti-TB treatment in the
early 1950s reduced the disease burden in developed
countries, TB remains a major global health problem in
many parts of the world, especially in Sub-Saharan African
(SSA) countries [2].
Only a minority of people exposed to Mycobacterium
tuberculosis (MTB) develop active TB [3]. In healthy
individuals, the immune system controls the infection
and patients can remain asymptomatic for prolonged
periods, a so-called latent infection, that may progress to
active TB with waning immuntity [4]. The HIV epidemic
has changed the dynamics of TB disease [5]. HIV infec-
tion increases the risk of progression to TB disease after
primary exposure [6], reinfection [7, 8] or from latent
TB [9, 10], and thereby the incidence and prevalence of
actual TB [11, 12], and the risk of transmission to unin-
fected persons [13, 14].
In 2004, the WHO and Stop TB Partnership developed
an interim policy on collaborative TB/HIV activities [15].
The four main TB prevention methods include intensified
case finding, isoniazid preventive therapy (IPT), tubercu-
losis infection control, and antiretroviral therapy (ART)
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[15]. So far, only ART has been implemented on a large
scale [16]. To improve TB prevention and treatment,
WHO launched an intervention package which is com-
prised of IPT, intensified case finding, and infection
control (three I’s) in parallel with ART. [17] IPT has
proven preventive efficacy in both non-HIV-infected
and HIV-infected individuals [18], however, only 32.5 %
of eligible individuals received IPT worldwide in 2012
[16, 19]. In a meta-analysis of eight placebo-controlled
trials involving 4136 HIV-infected participants [20], the
overall efficacy of IPT in preventing TB was 33 % al-
though reductions among Tuberculin Skin Test (TST)
negative patients were not statistically significant [20].
In a recently published study parallel therapy with IPT
and ART was more effective than the individual therap-
ies alone [21].
Importantly, most of the empirical evidence on effi-
cacy of IPT is derived from clinical trials conducted in
controlled settings. Evidence is lacking from routine
health care settings and some of the observational stud-
ies conducted are limited by methodological concerns;
for example, not all incorporate the time varying nature
of ART and IPT exposure. In addition, some studies do
not account for death as a competing event when esti-
mating the effect of IPT on TB incidence. Hence, this
retrospective cohort study aims to assess the effectiveness
of IPT in patients receiving ART in a routine care setting.
Methods
Setting
This retrospective cohort study was conducted at Dilla
University Referral Hospital in Ethiopia. Ethiopia has
adopted ART in 2005 [22] and implemented the com-
bined TB/HIV program including IPT in 2007 [23].
Study design & study population
This study included all patients who had been treated in
the TB and HIV/AIDS continuum of care between January
2007 and August 2013. Patients aged less than 15 years,
who did not have follow up information after first entry to
the cohort, had TB before enrolment to the chronic care
unit, or either died or were diagnosed with TB within
14 days of enrolment were excluded (Fig. 1).
Ethical approval was obtained from Dilla University
College of Health and Medical Sciences ethical review
board and Dilla University Hospital, Clinical and Prac-
tical training director office.
Data collection
Information on patient characteristics, severity of dis-
ease, treatments and outcomes was retrieved from
patient medical records by data clerks, with verification
of accuracy in a random sample. Data were entered in
the EpiData template version 3.0 (EpiData Association,
Odense, Denmark) and were anonymized prior to ana-
lysis. Baseline covariates included gender, age, ever
receiving cotrimoxazole prophylaxis, ART, weight, CD4
count, WHO stage of HIV infection, and functional sta-
tus. Follow-up visits for IPT and ART were monthly or
every two months, respectively. Further regular follow-
up visits were planned every six months for the first year
and once a year thereafter. During these visits CD4
counts, body weight, functional status and WHO stage
were recorded.
Outcome
The outcome of this study was the occurrence of TB or
all-cause mortality during follow-up. According to the
routine clinical guideline, TB was ascertained either by
a positive sputum smear, suggestive chest X-ray, sug-
gestive pathology or a positive sputum culture [23].
The date of death was determined by review of hospital
Fig 1 The schematic presentation of subjects selection for the final
analysis from HIV cohort of Dilla University Referral Hospital
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charts or interview of relatives. In the absence of the
above events, subjects were censored if they were lost
to follow-up or if they were alive at the end of the study
period (August 2013).
Interventions (Exposure)
IPT and ART were the determinants of interest in this
study and they were initiated according to local routine
clinical practice. All HIV patients without TB or previ-
ous history of TB were eligible for a course of IPT
(300 mg for six months), and it was provided free of
charge. The eligibility for IPT was determined by broad
clinical assessment to rule out TB up to 2010 [24].
Starting 2010, more stringent screening criteria were
used to rule out pre-existing TB and IPT was started in
patients without current cough, night sweats, weight
loss, or fever, in accordance with WHO recommenda-
tions [25]. TST testing was not required as screening
tool in both periods.
According to the national ART guidelines, patients
were eligible for ART when they developed more ad-
vanced HIV disease (WHO stage III or higher) or had
CD4 counts less than 200 cells/mm3 [3, 26].
Statistical methods
Data integrity was assessed and descriptive statistics
were generated. At baseline less than 5 % of data were
missing for WHO HIV disease stage, WHO functional
status, CD4 count and body weight; missing observa-
tions were imputed by multiple imputation and effect
estimates were pooled using Rubin’s rule [27]. Cox re-
gression was used to estimate unadjusted and adjusted
hazard ratios for the composite outcome of TB or death.
IPT and ART treatment status was included as time-
varying exposure and the estimates were adjusted for the
following baseline covariates: age, gender, cotrimoxazole
prophylaxis, weight, CD4 count, WHO stage and func-
tional status. If a patient on ART treatment began IPT,
person-time no longer accumulated in the ART alone
category, but rather person-time and subsequent events
contributed in the category labeled ‘on ART and treated
with IPT’. This person-time movement also occurred for
the small number of patients treated with IPT who then
began ART therapy. Patients who completed treatment
with IPT remained in the IPT treatment category until
the end of follow-up. Incidence rates of TB, death, and
composite outcome were calculated in each exposure
category. A considerable proportion of data were missing
during follow up and adjusted analysis was not possible
for covariates other than those measured at baseline.
Treatment with ART but not IPT was considered the ref-
erence group. The assumptions of Cox regression model
were assessed by examining Schoenfeld residuals for pro-
portional hazards, dfbeta’s for influential observation, and
martingale residuals for non-linearity [28]. The level of
significance was taken at p ≤0.05. All analysis was con-
ducted in SPSS version 20 [29] and R version 3.0.2 [30].
Results
Of the 4,091 patients enrolled in the comprehensive
follow-up program, 1,922 were included in the final
analysis (Fig. 1). Patients were excluded for one of the
following reasons: age less than 15 years (n = 296), lack
of follow-up information (n = 1,571), occurrence of TB
before enrolment to the chronic care unit (n = 234), TB
or death within the first fourteen days of enrolment to
the chronic care unit (n = 68). The were no statistically
significant differences in mean age and gender of cases
excluded due to a lack of follow-up information, those
participants lost to follow up and the participants
remaining in the cohort.
Three hundred seventy four (19.5 %) participants
received IPT during their follow up in the care program.
The majority of subjects (55.8 %) were females and close
to two third of the study subjects (60.5 %) were younger
than 34 years (Table 1). Eighty five percent of the study
subjects (n = 1635) were not on ART at baseline, but
almost all (n = 1919) received or started ART during
follow-up. In addition to IPT prophylaxis, many patients
(84.9 %) had received prophylactic co-trimoxazole. The
majority of the participants (64.3 %) had stage III HIV
disease at baseline. Most subjects were either at working
(58 %) or at ambulatory (36.4 %) functional status
according to the WHO operational definition. Sixty-five
percent of the subjects had a CD4 count less than 199
cells/mm3 and less than 4 % of the participants had CD4
counts above 350 cells/mm3. Almost half of the partici-
pants (n = 879) weighed less than 50 kgs (Table 1).
Five hundred seventy eight participants were lost to
follow-up during the study period and were censored,
together with the 460 participants alive at the end of the
study (Table 2). The median follow-up duration of the
cohort was 839 days with 5491.2 person-years (PYs) in
total. In total, 110 patients developed TB and 148 died
during the course of the study. TB was diagnosed based
on a positive sputum smear (n = 81), suggestive chest
X-ray (n = 13), suggestive pathology (n = 12) or a positive
sputum culture (n = 4). The incidence of TB (6.6 per 100
PYs), death (9.5 per 100 PYs), and the composite out-
come (16.1 per 100 PYs) was higher within the first six
months, with a decreasing trends in the following
months (Table 2).
Among the 374 patients receiving IPT, 45 (12 %) did
not complete six months of IPT: 34 were censored alive
during their IPT treatment, 7 were lost to follow up and
4 had an outcome (TB or death). Overall, the rate of TB
was higher in ART naïve participants (8.05 per 100 PYs)
followed by ART naïve participants yet treated with IPT
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(5.20 per 100 PYs) compared to those treated with both
ART and IPT (Table 3). In the crude analysis, male pa-
tients were at higher risk of developing TB or dying
[HR = 1.44; 95 % CI (1.12, 1.83)] (Table 4). Furthermore,
patients who were bed-ridden and those with more ad-
vanced HIV disease (WHO stage III or higher) at base-
line had an increased hazard of developing TB or death
in comparison to ambulatory patients or those with early
disease stages, respectively. Increasing baseline patient
body weight decreased the hazard of developing TB or
death by 2 % [HR = 0.98; 95 % CI (0.97, 0.99)]. With re-
spect to the patients’ entry point of care, those referred
from other health facilities had a lower hazard to de-
velop TB or die [HR = 0.61; 95 % CI (0.41, 0.87)] in com-
parison to patients referred from different departments
of the same hospital.
In the adjusted analysis, the same covariates appeared
associated with risk of TB or death (Table 4). In com-
parison to ambulatory patients, bedridden patients had
double the hazard to die or develop TB [aHR = 2.47;
Table 1 The Socio-demographic and baseline characteristics in IPT and non IPT cohorts in Dilla University Referral Hospital
Baseline covariates Non IPT cohort IPT cohort Total
N = 1548 N = 374 N = 1922
No. (%) No. (%) No. (%)
Gender Female 848 (54.8) 225 (11.768.2) 1073 (55.8)
Age group 15 – 25 years 333 (21.5) 78 (20.9) 411 (21.4)
26 – 29 years 238 (15.4) 63 (16.8) 301 (15.7)
30 – 34 years 355 (22.9) 94 (25.1) 449 (23.4)
35 – 39 years 268 (17.3) 58 (15.5) 326 (17.0)
40 – 99 years 354 (22.9) 81 (21.7) 435 (22.6)
ART at baseline No 1307 (84.4) 328 (87.7) 1635 (85.1)
Yes 241 (15.6) 46 (12.3) 287 (14.9)
Cotrimoxazole (ever use)* Yes 1290 (83.3) 341 (91.2) 1631 (84.9)
WHO stage of HIV disease* Stage I 141 (9.1) 39 (10.4) 180 (9.4)
Stage II 247 (16.0) 78 (20.9) 325 (16.9)
Stage III 1000 (64.6) 236 (63.1) 1236 (64.3)
Stage IV 160 (10.3) 21 (5.6) 181 (9.4)
WHO functional status* Ambulatory 590 (38.1) 110 (29.4) 700 (36.4)
Bedridden 99 (6.4) 8 (2.1) 107 (5.6)
Working 859 (55.5) 256 (68.4) 1115 (58.0)
CD4* 0 – 99 cells/mm3 477 (30.8) 76 (20.3) 553 (28.8)
100 – 199 cells/mm3 561 (36.3) 142 (38.0) 703 (36.6)
200 - 349 cells/mm3 446 (28.8) 145 (38.8) 591 (30.8)
350 + cells/mm3 63 (4.1) 11 (2.9) 74 (3.9)
Body weight < = 50 Kgs. 726 (47.5) 153 (41.6) 879 (46.4)
50-74 Kgs. 763 (50.0) 204 (55.4) 967 (51.0)
75 + Kgs. 38 (2.5) 11 (3.0) 49 (2.6)
Transfer in yes 160 (10.3) 36 (9.6) 196 (10.2)
Point of entry to care (Entry from) Referred from the same hospital 1197 (77.3) 296 (79.1) 1493 (77.7)
Self-referred 29 (1.9) 6 (1.6) 35 (1.8)
Referred from other health facilities 322 (20.8) 72 (19.3) 394 (20.5)
Outcomes Censored 1301 (84.0) 363 (97.1) 1664 (86.6)
TB 105 (6.8) 5 (1.3) 110 (5.7)
Death 142 (9.2) 6 (1.6) 148 (7.7)
Composite outcome TB or death 247 (16.0) 11 (2.9) 258 (13.4)
*:p value < 0.05. ART Antiretroviral therapy, HIV Human Immunodeficiency Virus, IPT Isoniazid Preventive Therapy, N Number of people, TB Tuberculosis, and
WHO World Health Organization
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95 % CI (1.62, 3.75)], and working patients had a 33 %
lower hazard to die or develop TB [aHR = 0.67; 95 % CI
(0.50, 0.89)]. With respect to the WHO staging, being in
WHO stage II or higher was associated with an
increased hazard of developing TB or death in compari-
son to patients in WHO stage I at baseline. Patients
transferred to the University Hospital chronic care unit
from primary health care units in the catchment area
had a lower hazard to develop TB or die in comparison
to patients who entered the cohort from different
departments of the same hospital (aHR = 0.39; 95 % CI
[0.18, 0.82]). The effects of age and baseline CD4 count
on TB or death were more or less nominal (Table 4).
In the unadjusted time dependent Cox regression
model, the combined treatment with IPT and ART low-
ered the hazard of TB or death by 65 % [HR = 0.35; 95 %
CI (0.16, 0.77)] compared to ART alone and no such
effect could be demonstrated for IPT in the absence of
ART [HR = 1.22; 95 % CI (0.45, 3.28)]. The combined
effect of IPT and ART lead to a 60 % reduction of the
hazard of death or TB in comparison to ART without
IPT after adjusting for baseline covariates [aHR = 0.40;
95 % CI (0.18, 0.87)]. It was not possible to reliably esti-
mate the effect IPT in patients not treated with ART as
there was little person time (77.0 PYs) available in this
treatment category.
Discussion
The estimated combined effect of IPT and ART on the
risk of TB or death in HIV infected patients was a 60 %
hazard reduction in comparison to ART without IPT
after adjusting for baseline confounders. Due to the little
patient time in the cohort for patients receiving IPT
without concomitant ART, the isolated effect of IPT
could not be reliably determined. Strikingly, only one
fifth of the HIV patients included in this study actually
received IPT.
These results are consistent with the results obtained
in controlled clinical trials. In a recently updated
Cochrane review of twelve clinical trials, IPT was associ-
ated with an overall TB risk reduction of 26 % in 8578
randomized HIV infected and TST positive participants
[20]. Moreover, recent empirical evidence has shown
that the combined benefit of ART and IPT was para-
mount in reducing the risk of TB and death (HR = 0.63,
95 % CI 0.41-0.94) [21, 31]. Further observational studies
conducted in Brazil [32], South Africa [33], and Hong
Kong [34] reported beneficial effect of combined therapy
on TB. Although ART reduces HIV disease progression
[35] and opportunistic infections including TB [36], the
recent WHO policy guidelines do not precisely define
how ART and IPT are best used together for optimal TB
risk reduction [37]. The biological mechanism of
Table 2 Follow up information of HIV cohort in Dilla University Referral Hospital from January 2007 to August 2013
Follow up time Total participants on






n (Per 100 PYs)
Death Reported
n (per 100 PYs)
Composite outcome
n (per 100 PYs)
Lost to follow up
n (per 100 PYs)
Censored
alive
Baseline (t = 0) 1922 (0) 12 289 0 (0) 0 (0) 0 (0) 0 (0) 0
6th month 1519 (865.2) 43 1293 57 (6.59) 82 (9.48) 139 (16.07) 175 (20.22) 89
12th month 1300 (703.1) 50 109 16 (2.28) 21 (2.99) 37 (5.26) 143 (20.34) 39
24th month 1028 (1165.7) 94 104 19 (1.63) 15 (1.29) 34 (2.92) 130 (11.15) 108
36th month 780 (893.7) 81 60 8 (0.90) 13 (1.46) 21 (2.35) 66 (7.39) 161
48th month
and beyond
626 (1863.4) 94 64 10 (0.54) 17 (0.91) 27 (1.45) 64 (3.44) 63
Total (5491.2) 374 1919 110 (2.00) 148 (2.70) 258 (4.70) 578 (10.53) 460
ART Antiretroviral therapy, IPT Isoniazid Preventive Therapy, n Number of people, PYs Person years, and TB Tuberculosis
Table 3 Incidence rate of endpoints (TB, death, and composite) in IPT and ART exposure category in HIV cohort of Dilla University
Hospital from January 2007 to August 2013
Exposure status Person years TB n (per 100 PYs) Death n (per 100 PYs) Composite n (per 100 PYs)
On ART, no IPT 3922.6 53 (1.35) 140 (3.57) 193 (4.92)
No ART, no IPT 645.9 52 (8.05) 2 (0.31) 54 (8.21)
No ART, treated with IPT 77.0 4 (5.20) 0 (0) 4 (5.20)
On ART, treated with IPT 845.7 1 (0.12) 6 (0.71) 7 (0.83)
Total 5491.2 110 (2.00) 148 (2.70) 258 (4.70)
ART Antiretroviral Therapy, IPT Isoniazid Preventive Therapy, n Number of events, PY Person Year, TB Tuberculosis
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combination therapy is that IPT reduces the burden of
MTB [38, 39], whereas ART decreases the risk of devel-
oping active TB by improving immune function [40–42].
These mechanisms appear complementary and the com-
bined use of these interventions might reasonably im-
prove outcomes in HIV patients.
Of note, self-referred patients or those who were
transferred from other health facilities had a lower risk
of developing TB or dying. These patients started ART
earlier compared to patients transferred to the HIV
treatment unit from the same hospital. A plethora of
studies reported that early diagnosis of HIV [43] and
early therapy [44] play a significant role in HIV disease
prevention and control. This study demonstrated that
most events (TB or death) occurred in the first six
months. This finding is consistent with a finding from
Thailand where most of TB episodes observed within
the first six months of enrolment [45].
The uptake of IPT in this study was lower than the
global estimate (32.5 %), although there was no clear
reason for this underutilization or under prescription
[19]. Possible reasons may be the health care profes-
sionals’ skepticism about potential drug resistance [24]
and subsequent underestimation of potential public
health impact [46], as well as lack of adequate means to
exclude a pre-existing TB infection prior to treatment
initiation.
As opposed to most clinical trials, this study used the
composite of TB or death as an outcome. Most trials
found significant TB risk reduction and statistically non-
significant effects in death prevention [21, 47]. As death
and occurrence of TB are competing events, we chose to
not separately assess the effect of IPT on these out-
comes. Competing event analysis would be a means to
reliability estimate the overall sub distribution hazard
and event specific hazards [48]. The low number of TB
or death cases in the IPT cohort, however, precluded a
formal competing risks analysis. A strength of our study
is the fit of a Cox regression model that includes time-
varying exposures to accommodate changes in treatment
status when IPT and/or ART are initiated. This possible
source of so-called time dependent bias is often
neglected, which can lead to overestimation of interven-
tion effects [49–52].
Most limitations of this study follow from the retro-
spective study design, such as the inability of assessing
Table 4 The crude and adjusted estimate of cox regression model fitting IPT and ART treatment status as time dependent
covariates for TB or death in HIV cohort of Dilla University hospital from January 2007 to August 2013
Covariates Crude HR 95 % CI Adjusted HRa 95% CI
Combination therapy On ART, no IPT 1 1
No ART, no IPT 1.08 (0.79, 1.47) 1.36 (0.97, 1.91)
No ART, treated with IPT 1.22 (0.45, 3.28) 1.86 (0.68, 5.10)
On ART, treated with IPT 0.35 (0.16, 0.77) 0.40 (0.18, 0.87)
Covariates: Crude HR 95 % CI Adjusted HRa 95% CI
Gender (male) 1.44 (1.12, 1.83) 1.56 (1.18, 2.06)
Age (years)b 1.01 (1.00, 1.03) 1.01 (0.99, 1.02)
Baseline body weight (Kg)c 0.98 (0.97, 0.99) 0.99 (0.97, 1.00)
Baseline CD4 count (Cells/mm3)d 1.00 (1.00, 1.01) 1.00 (0.999, 1.001)
Cotrimoxazole (ever use) 0.56 (0.43, 0.72) 0.72 (0.51, 1.02)
Baseline Function functional status Ambulatory 1 1
Bedridden 2.53 (1.72, 3.72) 2.47 (1.62, 3.75)
Working 0.56 (0.43, 0.73) 0.67 (0.50, 0.89)
Baseline WHO HIV disease stage Stage I 1 1
Stage II 1.12 (0.54, 2.31) 1.11 (0.53, 2.30)
Stage III 2.46 (1.33, 4.58) 2.14 (1.13, 4.06)
Stage IV 3.71 (1.87, 7.37) 2.25 (1.07, 4.74)
Patients transferred from other hospital 0.33 (0.17, 0.64) 0.39 (0.18, 0.82)
Entry from From the same facility 1 1
Self-referred 0.61 (0.20, 1.85) 0.71 (0.23, 2.15)
Referred from other facilities 0.61 (0.41, 0.87) 0.73 (0.48, 1.10)
aIPT & ART were adjusted to the baseline covariates: gender, age, baseline body weight, baseline CD4 count, cotrimoxazole prophylaxis (ever use), baseline WHO
functional status, baseline WHO stages, transfer history, and the entry point of care; HR Hazard Ratio, CI Confidence Interval, IPT Isoniazid Preventive Therapy, ART
Antiretroviral Therapy; bAge interval is in every five years; cBaseline body weight is in every 10kgs; dBaseline CD4 count is in every 50 cells/mm3
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time of HIV infection, precluding adjustment for length
time bias [52]. All HIV patients were eligible to receive
IPT as long as they fulfilled screening criteria [24, 25]. In
this study, however, less than 20 % of the participants
eligible for IPT received IPT, which may have created
confounding by indication and this is difficult to address
in observational studies [53]. The final model was
adjusted for baseline covariates, although this does not
control for effects of unmeasured confounders or time-
varying confounders. Finally, many patients were lost to
follow up and the underlying reasons for this could not
be derived from the clinical charts or ART database. Im-
portantly, there was little difference in the baseline char-
acteristics between patients with and without loss to
follow up and hence they were censored in the analysis.
Conclusion
In this retrospective cohort study, the combination of
IPT and ART reduced the hazard of TB or death in
HIV-infected patients by 60 % in comparison to treat-
ment with ART alone. Due to high levels of ART adop-
tion, it was not possible to make strong conclusion
about the benefits of IPT alone in the absence of ART.
Contrary to the evidence arising from this and other
studies, uptake of IPT in routine practice is very low
(<20 %). We, therefore, recommend studies to determine
the risk factors or predictors of the low IPT uptake,
quantify the risk of isoniazid-resistant TB after IPT use,
and elucidate the best strategies for (combined) initi-
ation of IPT and ART.
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